When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
PFE - Kinase inhibitors in focus on after Merck bid for ArQule
Pfizer Inc.
Merck's $2.7B bid for ArQule is yet another example of the Big Biopharma's high regard for oral kinase inhibitors for treating cancer. ArQule's lead drug is ARQ 531, an oral inhibitor of Bruton's tyrosine kinase (BTK).
More news on: Pfizer Inc., Eli Lilly and Company, AbbVie Inc., Healthcare stocks news,